scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX® On-Body Infusor
January 29, 2019 08:00 ET
|
scPharmaceuticals Inc.
Advancing FUROSCIX® with the SmartDose® Drug Delivery System Forecast 2018 year-end cash of $82 - $87 million and 2019 expenditures of $8 - $10 million per quarter BURLINGTON, Mass., Jan. 29, 2019 ...
scPharmaceuticals Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
November 13, 2018 08:00 ET
|
scPharmaceuticals Inc.
Resubmission of FURSOCIX® with the U.S. Food and Drug Administration (FDA) by year-end 2019 Balance sheet remains strong with over $95 million in cash BURLINGTON, Mass., Nov. 13, 2018 (GLOBE...
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
October 18, 2018 07:30 ET
|
scPharmaceuticals Inc.
Type A Post-Action Meeting Minutes Received BURLINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and...
scPharmaceuticals Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update
August 14, 2018 08:00 ET
|
scPharmaceuticals Inc.
Request for Type A meeting was granted by the U.S. Food and Drug Administration to discuss the Complete Response Letter received in June 2018 Balance sheet remains strong with over $100 million in...
scPharmaceuticals Announces Appointment of Two New Directors
July 24, 2018 08:00 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Appoints Frederick Hudson to Board of Directors
June 28, 2018 08:00 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Receives Complete Response Letter from the FDA for FUROSCIX®
June 13, 2018 08:00 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
May 31, 2018 08:30 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. to Present at the Jefferies 2018 Global Healthcare Conference
May 30, 2018 08:00 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports First Quarter 2018 Financial Results and Provides Business Update
May 07, 2018 16:01 ET
|
scPharmaceuticals Inc.
Company’s lead investigational product, FUROSCIX®, has a PDUFA date of June 23, 2018 Company has initiated staged commercialization activities for FUROSCIX BURLINGTON, Mass., May 07, 2018 (GLOBE...